Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Functional interplay between MDM2, p63/p73 and mutant p53.

Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dötsch V, Vousden KH.

Oncogene. 2015 Aug 13;34(33):4300-10. doi: 10.1038/onc.2014.359. Epub 2014 Nov 24.

2.

Behind the curtain: a look inside the publication process.

Ludwig RL, Kellogg A.

Radiol Technol. 2014 Sep-Oct;86(1):90-2. No abstract available.

PMID:
25224088
3.

How do I get a case study published?

Ludwig RL, Wood BD.

Radiol Technol. 2013 Jul-Aug;84(6):635-7. No abstract available.

PMID:
23861521
4.

Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death.

Cheung EC, Ludwig RL, Vousden KH.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20491-6. doi: 10.1073/pnas.1206530109. Epub 2012 Nov 26.

5.

The difference between peer review and nonpeer review.

Wood BD, Ludwig RL.

Radiol Technol. 2012 Sep-Oct;84(1):90-2. No abstract available.

PMID:
22988268
6.

Regulation of p53 stability and function by the deubiquitinating enzyme USP42.

Hock AK, Vigneron AM, Carter S, Ludwig RL, Vousden KH.

EMBO J. 2011 Nov 15;30(24):4921-30. doi: 10.1038/emboj.2011.419.

7.

Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP.

Vigneron AM, Ludwig RL, Vousden KH.

Genes Dev. 2010 Nov 1;24(21):2430-9. doi: 10.1101/gad.1954310.

8.

Mutant p53 drives invasion by promoting integrin recycling.

Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH.

Cell. 2009 Dec 24;139(7):1327-41. doi: 10.1016/j.cell.2009.11.026.

9.

Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.

Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li CC, Kenten JH, Beutler JA, Vousden KH, Weissman AM.

Cancer Res. 2007 Oct 1;67(19):9472-81.

10.

Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells.

Wilson JM, Henderson G, Black F, Sutherland A, Ludwig RL, Vousden KH, Robins DJ.

Bioorg Med Chem. 2007 Jan 1;15(1):77-86. Epub 2006 Oct 12.

PMID:
17064912
11.

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.

Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH.

Cancer Cell. 2005 Jun;7(6):547-59.

12.

Predictors of patient education by bone densitometry technologists.

Ludwig RL, Turner LW, O'Sullivan PS.

Radiol Technol. 2005 May-Jun;76(5):354-64.

PMID:
15921015
13.

HDM2 phosphorylation by MAPKAP kinase 2.

Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH.

Oncogene. 2005 Mar 17;24(12):1965-72.

PMID:
15688025
14.

Regulation of HDM2 activity by the ribosomal protein L11.

Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH.

Cancer Cell. 2003 Jun;3(6):577-87.

15.

Effective patient education in medical imaging: public perceptions of radiation exposure risk.

Ludwig RL, Turner LW.

J Allied Health. 2002 Fall;31(3):159-64.

PMID:
12227267
16.

Phosphorylation of HDM2 by Akt.

Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ, Vousden KH.

Oncogene. 2002 Mar 27;21(13):1955-62.

17.

C-terminal ubiquitination of p53 contributes to nuclear export.

Lohrum MA, Woods DB, Ludwig RL, Bálint E, Vousden KH.

Mol Cell Biol. 2001 Dec;21(24):8521-32.

18.

Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.

Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM.

J Biol Chem. 2000 Mar 24;275(12):8945-51.

19.

Analysis of the degradation function of Mdm2.

Kubbutat MH, Ludwig RL, Levine AJ, Vousden KH.

Cell Growth Differ. 1999 Feb;10(2):87-92.

20.

p14ARF links the tumour suppressors RB and p53.

Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH.

Nature. 1998 Sep 10;395(6698):124-5. No abstract available.

PMID:
9744267
21.

Regulation of Mdm2-directed degradation by the C terminus of p53.

Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH.

Mol Cell Biol. 1998 Oct;18(10):5690-8.

22.

Activation of p53 DNA binding activity by point mutation.

Marston NJ, Ludwig RL, Vousden KH.

Oncogene. 1998 Jun 18;16(24):3123-31.

23.

Rat embryo fibroblasts immortalized with simian virus 40 large T antigen undergo senescence upon its inactivation.

Gonos ES, Burns JS, Mazars GR, Kobrna A, Riley TE, Barnett SC, Zafarana G, Ludwig RL, Ikram Z, Powell AJ, Jat PS.

Mol Cell Biol. 1996 Sep;16(9):5127-38.

24.
25.

Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.

Crook T, Ludwig RL, Marston NJ, Willkomm D, Vousden KH.

Virology. 1996 Mar 1;217(1):285-92.

26.

Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.

Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH.

EMBO J. 1996 Feb 15;15(4):827-38.

27.

Retinoblastoma gene deletions in human glioblastomas.

Venter DJ, Bevan KL, Ludwig RL, Riley TE, Jat PS, Thomas DG, Noble MD.

Oncogene. 1991 Mar;6(3):445-8.

PMID:
2011399
28.

cDNA cloning of porcine transforming growth factor-beta 1 mRNAs. Evidence for alternate splicing and polyadenylation.

Kondaiah P, Van Obberghen-Schilling E, Ludwig RL, Dhar R, Sporn MB, Roberts AB.

J Biol Chem. 1988 Dec 5;263(34):18313-7.

29.

Complementary deoxyribonucleic acid cloning of bovine transforming growth factor-beta 1.

Van Obberghen-Schilling E, Kondaiah P, Ludwig RL, Sporn MB, Baker CC.

Mol Endocrinol. 1987 Oct;1(10):693-8.

PMID:
3153459
30.

Sacrococcygeal chordoma. A clinicoradiological study of 60 patients.

Smith J, Ludwig RL, Marcove RC.

Skeletal Radiol. 1987;16(1):37-44.

PMID:
3823959

Supplemental Content

Loading ...
Support Center